Matthew D Seftel
Overview
Explore the profile of Matthew D Seftel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seftel M, Musto G, Allan D, Bucher O, Hay K, Pasic I, et al.
Curr Oncol
. 2025 Jan;
32(1.
PMID: 39851926
In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs)...
2.
Parmar G, Green M, Ganz K, Seftel M, Allan D
Transfusion
. 2024 Sep;
64(11):2049-2054.
PMID: 39295246
Background: Allogeneic hematopoietic cell transplantation remains limited when stem cell registrants cannot be contacted, are not medically fit, are unavailable, or unwilling to proceed. In a recent report, registrants who...
3.
Parmar G, Seftel M, Ganz K, Blake J, Holovati J, Allan D
Curr Oncol
. 2024 May;
31(5):2542-2551.
PMID: 38785471
HLA-matched allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for many patients. Unrelated HLA-matched donors are the most frequently used donor for HCT. When more than one donor transplant...
4.
Seftel M, Terrell D, Cuker A, Cheung M, Pai M
Lancet Haematol
. 2024 May;
11(5):e317.
PMID: 38697728
No abstract available.
5.
Cuker A, Kunkle R, Bercovitz R, Byrne M, Djulbegovic B, Haberichter S, et al.
Blood Adv
. 2024 Apr;
8(11):2960-2963.
PMID: 38593461
The American Society of Hematology (ASH) develops a variety of resources that provide guidance to clinicians on the diagnosis and management of blood diseases. These resources include clinical practice guidelines...
6.
Seftel M, Pasic I, Parmar G, Bucher O, Allan D, Bhella S, et al.
Curr Oncol
. 2023 Nov;
30(11):9953-9967.
PMID: 37999143
Hematopoietic cell transplantation (HCT) is an established therapy for hematologic malignancies and serious non-malignant blood disorders. Despite its curative potential, HCT is associated with substantial toxicity and health resource utilization....
7.
Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M, et al.
Bone Marrow Transplant
. 2023 Oct;
59(1):76-84.
PMID: 37903992
Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host disease after hematopoietic cell transplantation (HCT); however, it might be associated with more infections. All patients who were ≥2 years old,...
8.
Papanicolaou G, Chen M, He N, Martens M, Kim S, Batista M, et al.
Transplant Cell Ther
. 2023 Sep;
30(1):114.e1-114.e16.
PMID: 37775070
Methods: Patients who underwent their first HCT between 2012 and 2017 for acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome and received a related haploidentical transplant with PTCy (HaploCy;...
9.
Bailey A, Blake J, Ganz K, Seftel M, Allan D
Transfusion
. 2023 Sep;
63(11):2114-2119.
PMID: 37750668
Background: The utility of unrelated donor registries that support allogeneic hematopoietic cell transplantation could be optimized through greater understanding of redundancy and rareness of HLA phenotypes. Methods: HLA phenotype rareness...
10.
Parmar G, Allan D, Morris G, Dibdin N, Ganz K, Mostert K, et al.
Curr Oncol
. 2023 Mar;
30(3):3549-3556.
PMID: 36975483
Background And Objectives: The COVID-19 pandemic profoundly influenced unrelated donor (UD) allogeneic peripheral blood stem cell (PBSC) collections. Changes included efforts to minimize COVID-19 exposure to donors and cryopreservation of...